170.69

8.83% -16.53

Pre-market: 169.03 -1.66 -0.97%

Guardant Health Inc (GH)

Overview News Price History Option Chain Financials Why GH Down? Discussions Forecast

Guardant Health Inc stock is traded at $170.69, with a volume of 3.39M. It is down -8.83% in the last 24 hours and up +5.75% over the past month. Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Previous Close:

$187.22

Open:

$188

24h Volume:

3.39M

Relative Volume:

1.60

Market Cap:

$22.91B

Revenue:

$1.08B

Net Income/Loss:

$-433.19M

P/E Ratio:

-50.20

EPS:

-3.4004

Net Cash Flow:

$-225.09M

1W Performance:

-3.96%

1M Performance:

+5.75%

6M Performance:

+90.37%

1Y Performance:

+169.31%

1-Day Range:

$170.05

$191.05

1-Week Range:

$170.05

$191.05

52-Week Range:

$61.00

$191.05

Guardant Health Inc Stock (GH) Company Profile

Name

Guardant Health Inc

Sector

Healthcare (1066)

Industry

Diagnostics & Research (50)

Phone

855-698-8887

Address

3100 HANOVER STREET, PALO ALTO

Employee

2,506

Twitter

@guardanthealth

Next Earnings Date

2026-11-04

Latest SEC Filings

GH's Discussions on Twitter

Compare GH vs TMO, DHR, NTRA, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GH Guardant Health Inc	170.69	23.79B	1.08B	-433.19M	-225.09M	-3.4004
TMO Thermo Fisher Scientific Inc	656.58	241.26B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	215.61	150.48B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	400.65	59.47B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	169.33	48.71B	7.23B	1.41B	1.09B	4.979
WAT Waters Corp	436.43	42.59B	3.77B	449.25M	240.68M	7.8556

Guardant Health Inc Stock (GH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-20-26	Reiterated	Canaccord Genuity	Buy
Feb-17-26	Initiated	Robert W. Baird	Outperform
Jan-05-26	Downgrade	Evercore ISI	Outperform → In-line
Dec-02-25	Resumed	Morgan Stanley	Overweight
Sep-25-25	Upgrade	Wolfe Research	Peer Perform → Outperform
Sep-22-25	Resumed	Wells Fargo	Overweight
Apr-10-25	Initiated	Mizuho	Outperform
Jan-23-25	Initiated	Barclays	Overweight
Jun-28-24	Upgrade	Guggenheim	Neutral → Buy
Jun-03-24	Resumed	Jefferies	Buy
Apr-24-24	Resumed	Craig Hallum	Buy
Dec-14-23	Initiated	Guggenheim	Neutral
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Nov-13-23	Upgrade	Raymond James	Mkt Perform → Outperform
Sep-28-23	Initiated	Bernstein	Outperform
Sep-27-23	Upgrade	Piper Sandler	Neutral → Overweight
Jul-05-23	Resumed	JP Morgan	Overweight
May-26-23	Upgrade	Citigroup	Neutral → Buy
May-05-23	Initiated	UBS	Buy
Mar-09-23	Downgrade	Citigroup	Buy → Neutral
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Nov-01-22	Downgrade	Piper Sandler	Overweight → Neutral
Oct-19-22	Initiated	Craig Hallum	Buy
Oct-06-22	Initiated	Stephens	Overweight
Aug-25-22	Initiated	Credit Suisse	Outperform
Jun-03-22	Initiated	Piper Sandler	Overweight
Apr-28-22	Resumed	BTIG Research	Buy
Feb-24-22	Reiterated	Canaccord Genuity	Buy
Feb-24-22	Reiterated	Citigroup	Buy
Feb-24-22	Reiterated	Cowen	Outperform
Feb-24-22	Reiterated	Morgan Stanley	Overweight
Feb-24-22	Reiterated	SVB Leerink	Outperform
Feb-24-22	Reiterated	Stifel	Buy
Feb-24-22	Reiterated	Wells Fargo	Overweight
Oct-15-21	Resumed	Cowen	Outperform
Jun-15-21	Initiated	Raymond James	Mkt Perform
Jun-03-21	Initiated	Goldman	Buy
May-25-21	Initiated	Wells Fargo	Overweight
Jan-11-21	Initiated	Stifel	Buy
Sep-09-20	Initiated	Morgan Stanley	Overweight
Jun-12-20	Initiated	BTIG Research	Buy
Feb-21-20	Initiated	Guggenheim	Buy
Jan-07-20	Initiated	Citigroup	Buy
Aug-07-19	Reiterated	Canaccord Genuity	Buy
Apr-16-19	Initiated	Canaccord Genuity	Buy
Apr-10-19	Upgrade	BofA/Merrill	Neutral → Buy
Feb-28-19	Reiterated	BofA/Merrill	Neutral
Oct-29-18	Initiated	BofA/Merrill	Neutral
Oct-29-18	Initiated	JP Morgan	Overweight
Oct-29-18	Initiated	William Blair	Outperform

View All

Guardant Health Inc Stock (GH) Latest News

Oct 01, 2026

Natera CEO Steve Chapman: Treatment on Molecular Recurrence Will Reshape Oncology in 5 Years - finance.biggo.com

Oct 01, 2026